IL157102A0 - Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods - Google Patents

Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Info

Publication number
IL157102A0
IL157102A0 IL15710202A IL15710202A IL157102A0 IL 157102 A0 IL157102 A0 IL 157102A0 IL 15710202 A IL15710202 A IL 15710202A IL 15710202 A IL15710202 A IL 15710202A IL 157102 A0 IL157102 A0 IL 157102A0
Authority
IL
Israel
Prior art keywords
anxiety
depression
treatment
methods
receptor antagonists
Prior art date
Application number
IL15710202A
Other languages
English (en)
Original Assignee
Synaptic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharma Corp filed Critical Synaptic Pharma Corp
Priority claimed from PCT/US2002/004608 external-priority patent/WO2002060392A2/en
Publication of IL157102A0 publication Critical patent/IL157102A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL15710202A 2001-01-31 2002-01-31 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods IL157102A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77534101A 2001-01-31 2001-01-31
PCT/US2002/004608 WO2002060392A2 (en) 2001-01-31 2002-01-31 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Publications (1)

Publication Number Publication Date
IL157102A0 true IL157102A0 (en) 2004-02-08

Family

ID=25104097

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15710202A IL157102A0 (en) 2001-01-31 2002-01-31 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
IL198759A IL198759A (en) 2001-01-31 2009-05-14 Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL198759A IL198759A (en) 2001-01-31 2009-05-14 Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety

Country Status (22)

Country Link
EP (3) EP2140862A3 (xx)
JP (3) JP4739650B2 (xx)
KR (1) KR20040041092A (xx)
CN (2) CN101406469B (xx)
AU (2) AU2002247149B2 (xx)
BG (1) BG108114A (xx)
BR (1) BR0206844A (xx)
CA (3) CA2438582C (xx)
CZ (1) CZ20032341A3 (xx)
EA (1) EA006486B1 (xx)
HR (1) HRP20030608A2 (xx)
HU (1) HUP0401858A3 (xx)
IL (2) IL157102A0 (xx)
IS (1) IS6880A (xx)
MX (1) MXPA03006812A (xx)
NO (1) NO20033388L (xx)
NZ (1) NZ527163A (xx)
PL (1) PL369270A1 (xx)
SK (1) SK9562003A3 (xx)
UA (1) UA74421C2 (xx)
YU (1) YU60803A (xx)
ZA (1) ZA200305686B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438582C (en) * 2001-01-31 2012-06-26 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
CN101973925B (zh) * 2010-10-15 2012-03-28 中国药科大学 具有抗炎活性的2-吲哚酮类化合物、其制备方法及医药用途
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
JP7171057B2 (ja) * 2016-12-29 2022-11-15 ミノリックス セラピューティクス エセ．エレ． ヘテロアリール化合物およびその使用
CN116063520A (zh) * 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN113317221B (zh) * 2021-06-18 2023-01-31 青岛百宜电器有限公司 自动梳毛机

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140441A (xx) * 1974-04-23 1975-11-11
GB1477349A (en) * 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
US4946956A (en) * 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
JPH02300264A (ja) * 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) * 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
HUT64323A (en) * 1992-06-09 1993-12-28 Richter Gedeon Vegyeszet Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
CN1104418C (zh) * 1994-06-15 2003-04-02 大塚制药株式会社 苯并杂环衍生物
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
PT765858E (pt) * 1995-04-12 2000-05-31 Ueno Seiyaku Oyo Kenkyujo Kk Derivados naftol e processo para a producao dos mesmos
CZ378497A3 (cs) * 1995-06-02 1998-04-15 Synthelabo Deriváty oxazolidinonu, způsob jejich přípravy a jejich terapeutické použití
WO1998055457A1 (en) * 1995-10-13 1998-12-10 Transitions Optical, Inc. Substituted naphthopyrans
FR2741072B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
DK0891978T3 (da) * 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
CN1240210A (zh) * 1998-04-17 2000-01-05 伊莱利利公司 取代的三环化合物
AU770309B2 (en) * 1998-06-05 2004-02-19 Regent Court Technologies Monoamine oxidase (MAO) inhibitors and uses thereof
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
IL146871A0 (en) * 1999-06-02 2002-08-14 Nps Pharma Inc Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
AU2735201A (en) * 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
CA2438582C (en) * 2001-01-31 2012-06-26 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Also Published As

Publication number Publication date
EP2140862A2 (en) 2010-01-06
HUP0401858A2 (hu) 2004-12-28
JP2010006813A (ja) 2010-01-14
IL198759A (en) 2013-06-27
EP1363638A2 (en) 2003-11-26
EP2140862A3 (en) 2010-02-17
CA2672805A1 (en) 2002-08-08
JP4739650B2 (ja) 2011-08-03
JP2004529089A (ja) 2004-09-24
NZ527163A (en) 2006-02-24
AU2008200385A1 (en) 2008-02-21
HRP20030608A2 (en) 2005-06-30
CA2438582C (en) 2012-06-26
CA2438582A1 (en) 2002-08-08
YU60803A (sh) 2006-05-25
CZ20032341A3 (cs) 2004-12-15
ZA200305686B (en) 2004-10-25
CN100446767C (zh) 2008-12-31
CN101406469A (zh) 2009-04-15
KR20040041092A (ko) 2004-05-13
CA2671776A1 (en) 2002-08-08
IS6880A (is) 2003-07-21
AU2008200385B2 (en) 2010-09-09
NO20033388D0 (no) 2003-07-29
CN101406469B (zh) 2012-06-13
CA2671776C (en) 2012-12-18
EP2140864A2 (en) 2010-01-06
EA200300850A1 (ru) 2004-06-24
EP2140864A3 (en) 2010-01-27
PL369270A1 (en) 2005-04-18
AU2002247149B2 (en) 2007-10-25
SK9562003A3 (en) 2004-04-06
UA74421C2 (uk) 2005-12-15
MXPA03006812A (es) 2004-10-15
EA006486B1 (ru) 2005-12-29
CN1499970A (zh) 2004-05-26
BG108114A (bg) 2005-03-31
NO20033388L (no) 2003-09-24
BR0206844A (pt) 2005-07-12
EP1363638A4 (en) 2010-01-06
JP2009173657A (ja) 2009-08-06
HUP0401858A3 (en) 2009-06-29

Similar Documents

Publication Publication Date Title
HK1060727A1 (en) Antagonists of mcp-1 function and methods of use thereof
HK1060728A1 (en) Antagonists of mcp-1 function and methods of use thereof
HK1064360A1 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
IL161041A0 (en) Mch antagonists for the treatment of obesity
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
HK1154504A1 (en) Chemokine receptor antagonists and methods of use thereof
PL370746A1 (en) Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
HUP0401535A3 (en) Somatostatin antagonists and their use
AU2002352036A8 (en) Method and device for the continuous testing of materials
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
AU2003300122A1 (en) Agonists and antagonists of the human odorant receptor or17-4 and uses thereof
GB2400436B (en) Real-time method for the detection and characterization of scale
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
AU782863C (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU2003298547A8 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
GB0124346D0 (en) Receptor and its use
AU2002324288A1 (en) Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
AU2002321774A1 (en) Agonists and antagonists of contabix for use in the treatment of metabolic disorders
AU2002339689A1 (en) Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002324296A1 (en) Agonists and antagonists of energen for use in the treatment of metabolic disorders
AU2002324299A1 (en) Genoxit agonists and antagonists for use in the treatment of metabolic disorders